AP&S Clinic

Terre Haute, Indiana 47804

0 studies enrolling now · 13 studies all time

What they study most

Bladder Cancer, Breast Cancer, Esophageal Cancer, Head and Neck Cancer, Lymphoma, B-Cell, Metastatic Breast Cancer, Multiple Myeloma, Non-Small Cell Lung Cancer, Ovarian Cancer, Prostate Cancer, Rectal Cancer, Small Cell Lung Cancer

Studies at this site

• Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer — Completed
• Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer — Stopped early
• Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas — Completed
• Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer — Completed
• Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer — Completed
• Imatinib Mesylate in Combination With Docetaxel for Advanced, Platinum-Refractory Ovarian Cancer — Completed
• Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer — Completed
• PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer — Stopped early
• Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer — Stopped early
• Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma — Stopped early
• Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck — Stopped early
• Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer — Stopped early
• Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Stopped early